79491-45-5

Usage

Uses

Used in Chemical Synthesis:
2,6-dibroMo-3-Methoxypyridine is used as a key intermediate in the synthesis of various organic compounds. Its unique structure and properties make it a valuable building block for the creation of new molecules with potential applications in various industries.
Used in Pharmaceutical Industry:
2,6-dibroMo-3-Methoxypyridine is used as a reagent in the development of pharmaceutical products. Its presence in the synthesis process can lead to the creation of new drugs with improved efficacy and reduced side effects.
Used in Agricultural Industry:
2,6-dibroMo-3-Methoxypyridine is used as a reagent in the production of agrochemicals, such as pesticides and herbicides. Its involvement in the synthesis process can contribute to the development of more effective and environmentally friendly products for agricultural use.

Upstream product

• 6602-33-1 2,6-dibromopyridin-3-ol 
• 74-88-4 methyl iodide 
• 109-00-2 3-HYDROXYPYRIDINE 

Downstream Products

• 79491-46-6 2,6-dibromo-3-methoxy-5-nitropyridine 
• 86271-56-9 (E)-2,6-diamino-5-(phenyldiazenyl)pyridin-3-ol 
• 138323-94-1 3-methoxypyridine-2,6-diamine 
• 1438286-74-8 2-bromo-3-methoxy-6-(1-(3,4,5-trimethoxyphenyl)vinyl)pyridine 
• 79491-48-8 2-bromo-5,6-dimethoxy-3-nitropyridine 
• 79491-47-7 2,6-dibromo-5-methoxypyridin-3-amine 
• 79491-49-9 3-amino-5,6-dimethoxypyridine 
• 64436-92-6 3-amino-5-methoxypyridine 

Relevant academic research and scientific papers

COMPOUNDS USEFUL TO TREAT PAIN

The present invention relates to compounds useful as bradykinin receptor antagonist, pharmaceutical composition comprising such compounds, and therapeutic use of the same. The present invention further relates to the combination of compounds useful for the therapeutic use. The present invention relates to the pharmaceutical composition comprising the compound and combination of compounds useful for treatment of urinary bladder pain, the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

Disclosed herein are compounds of Formula I'. Compounds of Formula I' inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase- dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists

A knowledge-based library of 2,3-dichlorophenylsulfonyl derivatives of commercially available aryl amines was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. Hits were required to be more potent than an existing indazole series, have better physicochemical properties (c log P 7.4 116 μg/mL), and be stable to acid and light. The benzimidazol-2-one core was identified as a hit suitable for further investigation. Substitution at N1 with small alkyl groups was tolerated; however, these analogues were inactive in the whole blood assay (pA2 7.4 (2.4), high LE (0.43), and solubility (152 μg/mL). In addition, 38 had human serum albumin binding of around 93% and met all the criteria for progression to lead optimisation.

Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511

Replacement of the piperazine sulfonamide portion of the PI3Kα inhibitor AMG 511 (1) with a range of aliphatic alcohols led to the identification of a truncated gem-dimethylbenzylic alcohol analog, 2-(5-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)amino)pyridin-3-yl)propan-2-ol (7). This compound possessed good in vitro efficacy and pharmacokinetic parameters and demonstrated an EC50 of 239 ng/mL in a mouse liver pharmacodynamic model measuring the inhibition of hepatocyte growth factor (HGF)-induced Akt Ser473 phosphorylation in CD1 nude mice 6 h post-oral dosing.

Thiophene-imidazopyridines

The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1

Synthetic Uses of the Sequential Ring Positional Reactivity in Pyridin-3-ol and Derivatives

A series of ring-substituted pyridin-3-ols has been prepared.The key to the scheme is the introduction of a bromo group to a specific ring position as a temporary blocking agent.As well as hydrogenolysis of the bromo function, nucleophilic displacement has also been investigated.